doi: 10.1016/j.stem.2016.08.012.
Overcoming Challenges Facing Advanced Therapies in the EU Market
Affiliations
- PMID: 27588746
- DOI: 10.1016/j.stem.2016.08.012
Item in Clipboard
Overcoming Challenges Facing Advanced Therapies in the EU Market
Cell Stem Cell.
.
Free article
Abstract
While advanced therapy medicinal products offer great clinical promise, most EU-approved products have not achieved satisfactory commercial performance. Here we highlight a number of issues that prevent current products from obtaining commercial success and pitfalls that developers must overcome in future product development.
Copyright © 2016 Elsevier Inc. All rights reserved.
Similar articles
-
The Small- and Medium-sized Enterprises Office (SME Office) at the European Medicines Agency.Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010 Jan;53(1):20-3. doi: 10.1007/s00103-009-0989-z. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2010. PMID: 20101799
-
EU orphan regulation--ten years of application.Food Drug Law J. 2010;65(4):639-69, i-ii. Food Drug Law J. 2010. PMID: 24479246
-
Creating conditions for the success of the French industrial advanced therapy sector.Therapie. 2015 Jan-Feb;70(1):69-94. doi: 10.2515/therapie/2015005. Epub 2015 Mar 6. Therapie. 2015. PMID: 25747840 English, French.
-
EU marketing authorization review of orphan and non-orphan drugs does not differ.Drug Discov Today. 2013 Oct;18(19-20):1001-6. doi: 10.1016/j.drudis.2013.06.012. Epub 2013 Jul 5. Drug Discov Today. 2013. PMID: 23835230 Review.
-
EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.Drug Discov Today. 2018 Jul;23(7):1328-1333. doi: 10.1016/j.drudis.2018.03.008. Epub 2018 Mar 21. Drug Discov Today. 2018. PMID: 29574211 Review.
Cited by
-
Trends in Articular Cartilage Tissue Engineering: 3D Mesenchymal Stem Cell Sheets as Candidates for Engineered Hyaline-Like Cartilage.Cells. 2021 Mar 13;10(3):643. doi: 10.3390/cells10030643. Cells. 2021. PMID: 33805764 Free PMC article. Review.
-
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.Appl Health Econ Health Policy. 2022 Jul;20(4):501-524. doi: 10.1007/s40258-021-00714-9. Epub 2022 Apr 4. Appl Health Econ Health Policy. 2022. PMID: 35368231 Free PMC article.
-
Disease Resistance and the Definition of Genetic Enhancement.Front Genet. 2017 Apr 10;8:40. doi: 10.3389/fgene.2017.00040. eCollection 2017. Front Genet. 2017. PMID: 28443132 Free PMC article.
-
Adaptation through Collaboration: Developing Novel Platforms to Advance the Delivery of Advanced Therapies to Patients.Front Med (Lausanne). 2017 May 29;4:56. doi: 10.3389/fmed.2017.00056. eCollection 2017. Front Med (Lausanne). 2017. PMID: 28611985 Free PMC article. Review.
-
Addressing Pressing Needs in the Development of Advanced Therapies.Front Bioeng Biotechnol. 2017 Sep 25;5:55. doi: 10.3389/fbioe.2017.00055. eCollection 2017. Front Bioeng Biotechnol. 2017. PMID: 28993805 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
